questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Lipoprotéines
Apolipoprotéines
Apolipoprotéines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Apolipoprotéines
Tests de laboratoire
Apolipoprotéines
Analyse sanguine
Maladies cardiovasculaires
Apolipoprotéines
Imagerie médicale
Apolipoprotéines
Athérosclérose
Apolipoprotéines
Symptômes
5
Douleur thoracique
Apolipoprotéines
Métabolisme lipidique
Apolipoprotéines
Cholestérol
Apolipoprotéines
Accident vasculaire cérébral
Apolipoprotéines
Prévention
5
Prévention
Apolipoprotéines
Tabagisme
Apolipoprotéines
Contrôle de santé
Apolipoprotéines
Hydratation
Apolipoprotéines
Traitements
5
Statines
Apolipoprotéines
Médicaments hypolipémiants
Apolipoprotéines
Régime alimentaire
Apolipoprotéines
Exercice physique
Apolipoprotéines
Médecine complémentaire
Apolipoprotéines
Complications
5
Maladies cardiovasculaires
Apolipoprotéines
Maladies hépatiques
Apolipoprotéines
Santé rénale
Apolipoprotéines
Inflammation
Apolipoprotéines
Facteurs de risque
5
Hérédité
Apolipoprotéines
Vieillissement
Apolipoprotéines
Mode de vie sédentaire
Apolipoprotéines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines : Questions médicales les plus fréquentes",
"headline": "Apolipoprotéines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Apolipoprotéines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lipoprotéines",
"url": "https://questionsmedicales.fr/mesh/D008074",
"about": {
"@type": "MedicalCondition",
"name": "Lipoprotéines",
"code": {
"@type": "MedicalCode",
"code": "D008074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines M",
"alternateName": "Apolipoproteins M",
"url": "https://questionsmedicales.fr/mesh/D000075243",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines M",
"code": {
"@type": "MedicalCode",
"code": "D000075243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines A",
"alternateName": "Apolipoproteins A",
"url": "https://questionsmedicales.fr/mesh/D001054",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines A",
"code": {
"@type": "MedicalCode",
"code": "D001054",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-I",
"alternateName": "Apolipoprotein A-I",
"url": "https://questionsmedicales.fr/mesh/D016632",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-I",
"code": {
"@type": "MedicalCode",
"code": "D016632",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-II",
"alternateName": "Apolipoprotein A-II",
"url": "https://questionsmedicales.fr/mesh/D016633",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-II",
"code": {
"@type": "MedicalCode",
"code": "D016633",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-V",
"alternateName": "Apolipoprotein A-V",
"url": "https://questionsmedicales.fr/mesh/D000072040",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-V",
"code": {
"@type": "MedicalCode",
"code": "D000072040",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.575"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines B",
"alternateName": "Apolipoproteins B",
"url": "https://questionsmedicales.fr/mesh/D001055",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines B",
"code": {
"@type": "MedicalCode",
"code": "D001055",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-48",
"alternateName": "Apolipoprotein B-48",
"url": "https://questionsmedicales.fr/mesh/D053283",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-48",
"code": {
"@type": "MedicalCode",
"code": "D053283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.240"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-100",
"alternateName": "Apolipoprotein B-100",
"url": "https://questionsmedicales.fr/mesh/D053299",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-100",
"code": {
"@type": "MedicalCode",
"code": "D053299",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.249"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines C",
"alternateName": "Apolipoproteins C",
"url": "https://questionsmedicales.fr/mesh/D001056",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines C",
"code": {
"@type": "MedicalCode",
"code": "D001056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-I",
"alternateName": "Apolipoprotein C-I",
"url": "https://questionsmedicales.fr/mesh/D053302",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-I",
"code": {
"@type": "MedicalCode",
"code": "D053302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-II",
"alternateName": "Apolipoprotein C-II",
"url": "https://questionsmedicales.fr/mesh/D053304",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-II",
"code": {
"@type": "MedicalCode",
"code": "D053304",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-III",
"alternateName": "Apolipoprotein C-III",
"url": "https://questionsmedicales.fr/mesh/D053305",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-III",
"code": {
"@type": "MedicalCode",
"code": "D053305",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines D",
"alternateName": "Apolipoproteins D",
"url": "https://questionsmedicales.fr/mesh/D053399",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines D",
"code": {
"@type": "MedicalCode",
"code": "D053399",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines E",
"alternateName": "Apolipoproteins E",
"url": "https://questionsmedicales.fr/mesh/D001057",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines E",
"code": {
"@type": "MedicalCode",
"code": "D001057",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E2",
"alternateName": "Apolipoprotein E2",
"url": "https://questionsmedicales.fr/mesh/D053329",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E2",
"code": {
"@type": "MedicalCode",
"code": "D053329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E3",
"alternateName": "Apolipoprotein E3",
"url": "https://questionsmedicales.fr/mesh/D053318",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E3",
"code": {
"@type": "MedicalCode",
"code": "D053318",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E4",
"alternateName": "Apolipoprotein E4",
"url": "https://questionsmedicales.fr/mesh/D053327",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E4",
"code": {
"@type": "MedicalCode",
"code": "D053327",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines L",
"alternateName": "Apolipoproteins L",
"url": "https://questionsmedicales.fr/mesh/D000075943",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines L",
"code": {
"@type": "MedicalCode",
"code": "D000075943",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine L1",
"alternateName": "Apolipoprotein L1",
"url": "https://questionsmedicales.fr/mesh/D000075944",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine L1",
"code": {
"@type": "MedicalCode",
"code": "D000075944",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines",
"alternateName": "Apolipoproteins",
"code": {
"@type": "MedicalCode",
"code": "D001053",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Joan Carles Escolà-Gil",
"url": "https://questionsmedicales.fr/author/Joan%20Carles%20Escol%C3%A0-Gil",
"affiliation": {
"@type": "Organization",
"name": "Institut de Recerca Sant Pau, 08041 Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Robert A Hegele",
"url": "https://questionsmedicales.fr/author/Robert%20A%20Hegele",
"affiliation": {
"@type": "Organization",
"name": "Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Catherine Mounier",
"url": "https://questionsmedicales.fr/author/Catherine%20Mounier",
"affiliation": {
"@type": "Organization",
"name": "Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada."
}
},
{
"@type": "Person",
"name": "Allan Sniderman",
"url": "https://questionsmedicales.fr/author/Allan%20Sniderman",
"affiliation": {
"@type": "Organization",
"name": "Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36055261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1756196"
}
},
{
"@type": "ScholarlyArticle",
"name": "The prothrombin time/international normalized ratio predicts prognosis in cardiogenic shock.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/37139569",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MCA.0000000000001241"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population.",
"datePublished": "2022-10-15",
"url": "https://questionsmedicales.fr/article/36292752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes13101867"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of prothrombin time, thrombin time and activated partial thromboplastin time levels with preeclampsia: a systematic review and meta-analysis.",
"datePublished": "2024-05-13",
"url": "https://questionsmedicales.fr/article/38741046",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12884-024-06543-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Data mining for prothrombin time and international normalized ratio reference intervals in children.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36302050",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0276884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D008074"
},
{
"@type": "ListItem",
"position": 5,
"name": "Apolipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D001053"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Apolipoprotéines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Apolipoprotéines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Apolipoprotéines",
"description": "Comment diagnostiquer une anomalie des apolipoprotéines ?\nQuels tests sont utilisés pour évaluer les apolipoprotéines ?\nLes apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?\nPeut-on détecter des apolipoprotéines par imagerie ?\nQuels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Apolipoprotéines",
"description": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?\nLes apolipoprotéines affectent-elles le métabolisme ?\nComment les apolipoprotéines influencent-elles le cholestérol ?\nDes symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?\nLes apolipoprotéines sont-elles liées à l'obésité ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Apolipoprotéines",
"description": "Comment prévenir les anomalies d'apolipoprotéines ?\nLe tabagisme influence-t-il les apolipoprotéines ?\nLe stress a-t-il un impact sur les apolipoprotéines ?\nLes contrôles réguliers de santé sont-ils importants ?\nL'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Apolipoprotéines",
"description": "Quels traitements existent pour les anomalies d'apolipoprotéines ?\nLes médicaments peuvent-ils normaliser les apolipoprotéines ?\nLe régime alimentaire influence-t-il les apolipoprotéines ?\nLes exercices physiques affectent-ils les niveaux d'apolipoprotéines ?\nLes traitements naturels peuvent-ils aider les apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Apolipoprotéines",
"description": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?\nLes apolipoprotéines anormales peuvent-elles causer des diabètes ?\nLes troubles hépatiques sont-ils liés aux apolipoprotéines ?\nLes apolipoprotéines affectent-elles la santé rénale ?\nLes apolipoprotéines peuvent-elles influencer l'inflammation ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Apolipoprotéines",
"description": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?\nL'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?\nLe vieillissement influence-t-il les niveaux d'apolipoprotéines ?\nLe sexe a-t-il un impact sur les apolipoprotéines ?\nLe mode de vie sédentaire est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Prothrombin+Time#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des apolipoprotéines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'apolipoprotéines sont effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les apolipoprotéines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages des apolipoprotéines A1 et B sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux d'apolipoprotéines sont associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des apolipoprotéines par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la détection se fait principalement par des analyses sanguines, pas par imagerie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'athérosclérose peuvent indiquer des anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés peuvent entraîner des douleurs thoraciques ou des crises cardiaques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle clé dans le métabolisme lipidique et peuvent causer des troubles."
}
},
{
"@type": "Question",
"name": "Comment les apolipoprotéines influencent-elles le cholestérol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles transportent le cholestérol dans le sang, influençant les niveaux de cholestérol total."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être associées à des troubles neurologiques comme l'AVC."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées à l'obésité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être observés chez les personnes obèses."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies d'apolipoprotéines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain avec une alimentation équilibrée et de l'exercice régulier."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les apolipoprotéines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque d'anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les apolipoprotéines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers de santé sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans de santé réguliers aident à détecter les anomalies tôt."
}
},
{
"@type": "Question",
"name": "L'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hydratation est essentielle pour le métabolisme lipidique."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les anomalies d'apolipoprotéines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines et les changements de mode de vie sont souvent recommandés."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils normaliser les apolipoprotéines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aider à réguler les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il les apolipoprotéines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un régime riche en fibres et faible en graisses saturées peut aider."
}
},
{
"@type": "Question",
"name": "Les exercices physiques affectent-ils les niveaux d'apolipoprotéines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les traitements naturels peuvent-ils aider les apolipoprotéines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes et suppléments peuvent soutenir la santé lipidique, mais consultez un médecin."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies cardiovasculaires, des AVC et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines anormales peuvent-elles causer des diabètes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont liées à un risque accru de diabète de type 2."
}
},
{
"@type": "Question",
"name": "Les troubles hépatiques sont-ils liés aux apolipoprotéines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être associés à des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles la santé rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines peuvent-elles influencer l'inflammation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés sont souvent associés à des états inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme, une mauvaise alimentation et le manque d'exercice sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiovasculaires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le vieillissement influence-t-il les niveaux d'apolipoprotéines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut entraîner des modifications des niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le sexe a-t-il un impact sur les apolipoprotéines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des différences hormonales peuvent influencer les niveaux d'apolipoprotéines entre les sexes."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque d'anomalies d'apolipoprotéines."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institut de Recerca Sant Pau, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Mental Health and Society Division, Douglas Mental Health University Institute, Montreal, QC, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China. yunshucoffee@sina.com.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China. yunshucoffee@sina.com.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lin Cui Road, Beijing, 100101, China. zhangxy@psych.ac.cn.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Neurology University of Kansas Medical Center, Kansas City, KS 66160, USA.
University of Kansas Alzheimer's Disease Center, Kansas City, KS 66160, USA.
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada. Electronic address: mlk@robarts.ca.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
School of Public Health, Guangdong Medical University, Zhanjiang, 524023, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Public Health Foundation India, Gurugram, Haryana, India; Centre for Chronic Disease Control, New Delhi, India; London School of Hygiene & Tropical Medicine, United Kingdom. Electronic address: dprabhakaran@ccdcindia.org.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China.
Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Center for Biomedical Research (CEBIOR), Faculty of Medicine, Universitas Diponegoro, Semarang 50275, Central Java, Indonesia.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, University of Marlyand, College Park, MD 20742, USA.
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Division of Biostatistics, School of Medicine, University of California Davis, Davis, CA 95616, USA.
Publications dans "Apolipoprotéines" :
Mixing studies have long been in the clinical laboratory armamentarium for investigating unexpected, prolonged activated partial thromboplastin time (aPTT) or prothrombin time (PT). The purpose of the...
The study investigates the prognostic impact of the prothrombin time/international normalized ratio (PT/INR) in patients with cardiogenic shock....
Despite ongoing improvements regarding the treatment of cardiogenic shock patients, intensive care unit (ICU)-related mortality in cardiogenic shock patients remains unacceptably high. Limited data re...
All consecutive patients with cardiogenic shock from 2019 to 2021 were included at one institution. Laboratory values were collected from the day of disease onset (day 1) and days 2, 3, 4 and 8. The p...
Two hundred twenty-four cardiogenic shock patients were included with a rate of all-cause mortality at 30 days of 52%. The median PT/INR on day 1 was 1.17. The PT/INR on day 1 was able to discriminate...
Baseline PT/INR and an increase of the PT/INR during the course of ICU treatment were associated with the risk of 30-day all-cause mortality in cardiogenic shock patients....
(1) Background: The purpose of this study was to evaluate the effect of gene polymorphisms on prothrombin time (PT) and activated partial thromboplastin time (APTT) in a healthy Chinese population. (2...
Preeclampsia (PE), an obstetric disorder, remains one of the leading causes of maternal and infant mortality worldwide. In individuals with PE, the coagulation-fibrinolytic system is believed to be am...
This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Articles relevant to the study, published from July 26, 2013, to July 26, 2023, were systematically sea...
A total of 30 articles, involving 5,964 individuals (2,883 with PE and 3,081 as normotensive pregnant mothers), were included in this study. The overall pooled SMD for PT, APTT, and TT between PE and ...
The meta-analysis underscores the association between PE and prolonged PT and APTT. This suggests that evaluating coagulation parameters like PT, APTT, and TT in pregnant women could offer easily acce...
Reference intervals (RIs) help physicians in differentiating healthy from sick individuals. The prothrombin time (PT) and International normalized ratio (INR) fluctuate in coagulation pathway defects ...
COVID-19 is a viral disease caused by a new strain of corona virus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identif...
A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and...
Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83-0.95). PT also differentiated mild COVID-19 patients fro...
Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. The...
The regimens for factor Xa (FXa) inhibitors (apixaban, edoxaban, and rivaroxaban) vary with venous thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). The dosage and duration of FXa inhi...
Coagulopathy is a common complication of heart failure (HF), but the prognostic significance of coagulation abnormalities for HF is still poorly understood. This investigation sought to elucidate the ...
In this retrospective study, we extracted data from a publicly accessible database for hospitalized HF patients in China. The admission laboratory findings were screened by the least absolute shrinkag...
A total of 1505 HF patients were included, of whom 58.7% were female and 35.6% were between 70 and 79 y. In LASSO procedure, admission PTA level was included in optimized models for short-term readmis...
Low admission PTA level is associated with an increased risk of 90-day and 180-day hospital readmission in patients with HF....
Dentists should consult with the patient's hepatologist to obtain the most recent medical records with liver function tests and a coagulation panel. In the absence of severe liver dysfunction and with...
Prolonged prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) are frequently seen in newly diagnosed paediatric leukaemia patients (NDPLP), which can lead to delayed diagnostic a...